Growth Metrics

Pfizer (PFE) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $11.0 billion.

  • Pfizer's Long-Term Deferred Tax rose 3968.9% to $11.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 billion, marking a year-over-year increase of 3968.9%. This contributed to the annual value of $8.7 billion for FY2024, which is 4992.77% down from last year.
  • Pfizer's Long-Term Deferred Tax amounted to $11.0 billion in Q3 2025, which was up 3968.9% from $10.3 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Long-Term Deferred Tax ranged from a high of $17.3 billion in Q4 2023 and a low of $2.5 billion during Q2 2021
  • Over the past 5 years, Pfizer's median Long-Term Deferred Tax value was $7.9 billion (recorded in 2024), while the average stood at $8.0 billion.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first skyrocketed by 15991.09% in 2022, then crashed by 4992.77% in 2024.
  • Over the past 5 years, Pfizer's Long-Term Deferred Tax (Quarter) stood at $9.0 billion in 2021, then surged by 47.67% to $13.3 billion in 2022, then skyrocketed by 30.41% to $17.3 billion in 2023, then plummeted by 49.93% to $8.7 billion in 2024, then increased by 27.55% to $11.0 billion in 2025.
  • Its Long-Term Deferred Tax was $11.0 billion in Q3 2025, compared to $10.3 billion in Q2 2025 and $9.5 billion in Q1 2025.